

NEWS RELEASE

SHELDON INWENTASH AND JOINT ACTOR DISPOSE OF SECURITIES OF AUXICO RESOURCES CANADA INC.

Toronto, Ontario, January 19, 2022 – Sheldon Inwentash (“Inwentash”) announces that through a series of transactions (“Dispositions”) ending on January 13, 2022, Inwentash and ThreeD Capital Inc. (the “Joint Actor”), disposed of ownership and control of an aggregate 538,500 common shares (the “Subject Shares”) of Auxico Resources Canada Inc. (the “Company” or “AUAG”). The Subject Shares represented approximately 0.8% of all issued and outstanding common shares of the Company on January 13, 2022. As a result of the Dispositions, the percentage ownership held by Inwentash and the Joint Actor decreased by 5.4% from the last early warning report filed in which Inwentash, along with the Joint Actor, reported an 18.6% ownership on a partially diluted basis assuming the exercise of convertible debentures and options held.

Immediately before the Dispositions described above, Inwentash and the Joint Actor held an aggregate of 4,035,500 common shares, 500,000 options, and convertible debentures entitling the Inwentash and the Joint Actor to acquire 5,500,000 common shares of AUAG, representing approximately 7.1% of the issued and outstanding common shares of the Company (or approximately 15.9% on a partially diluted basis, assuming exercise of the convertible debentures and options held). Of this total, Inwentash held an aggregate of 2,323,000 common shares, 500,000 options, and convertible debentures allowing Inwentash to acquire an additional 3,500,000 common shares of the Company, representing approximately 4.1% of the issued and outstanding common shares of AUAG (or approximately 10.3% on a partially diluted basis, assuming exercise of the convertible debentures and options held). The Joint Actor held an aggregate of 1,712,000 common shares and convertible debentures allowing the Joint Actor to acquire an additional 2,000,000 common shares of the Company, representing approximately 3.0% of the issued and outstanding common shares of AUAG (or approximately 6.3% on a partially diluted basis, assuming exercise of the convertible debentures held).

Immediately following the Dispositions described above, Inwentash and the Joint Actors held an aggregate of 3,497,000 common shares, 500,000 options, and convertible debentures entitling Inwentash and the Joint Actor to acquire an additional 5,500,000 common shares of the Company, representing approximately 5.3% of the issued and outstanding common shares of AUAG (or approximately 13.2% on a partially diluted basis, assuming exercise of the convertible debentures and options held). Of this total, Inwentash held an aggregate of 2,323,000 common shares, 500,000 options, and convertible debentures entitling Inwentash to acquire an additional 3,500,000, representing approximately 3.5% of the issued and outstanding common shares of the Company (or approximately 9.1% assuming exercise of the convertible debentures and options held). The Joint Actor held an aggregate of 1,174,000 common shares and convertible debentures entitling the Joint Actor to acquire an additional 2,000,000 common shares of the Company, representing approximately 1.8% of the issued and outstanding common shares of AUAG (or approximately 4.7% on a partially diluted basis, assuming exercise of the convertible debentures held).

The Subject Shares were disposed of through the facilities of the Canadian Securities Exchange. The holdings of securities of the Company by Inwentash and the Joint Actor are managed for investment purposes, and Inwentash or the Joint Actor could increase or decrease its investments

in the Company at any time, or continue to maintain its current position, depending on market conditions or any other relevant factor.

The aggregate consideration received for the Subject Shares was \$653,733 or approximately \$1.21 per Subject Share.

Additional Information

A copy of the applicable securities report filed in connection with the matters set forth above may be obtained by contacting:

Sheldon Inwentash
130 Spadina Avenue, Suite 401
Toronto, ON
M5V 2L4

Tel: 416-941-8900